RxBNAvastin
bevacizumab
1 reference · 6 biosimilar-only
Reference Product
Avastin
bevacizumab
351(a) Reference Product (Approval Date 26-Feb-2004)
ApplicantGenentech, Inc.
BLA125085
RouteIntravenous
Presentation
Single-Dose Vial
Avastin
bevacizumab
351(a) Reference Product (Approval Date 26-Feb-2004)
ApplicantGenentech, Inc.
BLA125085
·RouteIntravenous
Presentation
Single-Dose Vial
Interchangeable Biosimilars
No interchangeable biosimilars in this group.
Biosimilars (not interchangeable)
Alymsys
bevacizumab-maly
351(k) Biosimilar (Approval Date 13-Apr-2022)
ApplicantAmneal Pharmaceuticals LLC
BLA761231
RouteIntravenous
Presentation
Single-Dose Vial
Alymsys
bevacizumab-maly
351(k) Biosimilar (Approval Date 13-Apr-2022)
ApplicantAmneal Pharmaceuticals LLC
BLA761231
·RouteIntravenous
Presentation
Single-Dose Vial
Avzivi
bevacizumab-tnjn
351(k) Biosimilar (Approval Date 6-Dec-2023)
ApplicantBio-Thera Solutions, Ltd.
BLA761198
RouteIntravenous
Presentation
Single-Dose Vial
Avzivi
bevacizumab-tnjn
351(k) Biosimilar (Approval Date 6-Dec-2023)
ApplicantBio-Thera Solutions, Ltd.
BLA761198
·RouteIntravenous
Presentation
Single-Dose Vial
Jobevne
bevacizumab-nwgd
351(k) Biosimilar (Approval Date 9-Apr-2025)
ApplicantBiocon Biologics Inc.
BLA761175
RouteIntravenous
Presentation
Single-Dose Vial
Jobevne
bevacizumab-nwgd
351(k) Biosimilar (Approval Date 9-Apr-2025)
ApplicantBiocon Biologics Inc.
BLA761175
·RouteIntravenous
Presentation
Single-Dose Vial
Mvasi
bevacizumab-awwb
351(k) Biosimilar (Approval Date 14-Sep-2017)
ApplicantAmgen Inc.
BLA761028
RouteIntravenous
Presentation
Single-Dose Vial
Mvasi
bevacizumab-awwb
351(k) Biosimilar (Approval Date 14-Sep-2017)
ApplicantAmgen Inc.
BLA761028
·RouteIntravenous
Presentation
Single-Dose Vial
Vegzelma
bevacizumab-adcd
351(k) Biosimilar (Approval Date 27-Sep-2022)
ApplicantCELLTRION, Inc.
BLA761268
RouteIntravenous
Presentation
Single-Dose Vial
Vegzelma
bevacizumab-adcd
351(k) Biosimilar (Approval Date 27-Sep-2022)
ApplicantCELLTRION, Inc.
BLA761268
·RouteIntravenous
Presentation
Single-Dose Vial
Zirabev
bevacizumab-bvzr
351(k) Biosimilar (Approval Date 27-Jun-2019)
ApplicantPfizer Inc.
BLA761099
RouteIntravenous
Presentation
Single-Dose Vial
Zirabev
bevacizumab-bvzr
351(k) Biosimilar (Approval Date 27-Jun-2019)
ApplicantPfizer Inc.
BLA761099
·RouteIntravenous
Presentation
Single-Dose Vial